Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, announces that both the US Food and Drug Administration (FDA) and Finnish Medicines Agency (FIMEA) have cleared Faron's Investigational New Drug (IND) application to begin the company sponsored BEXMAB study. BEXMAB is a novel phase I/II study to assess safety, tolerability and preliminary efficacy of bexmarilimab, Faron's wholly-owned investigational precision cancer immunotherapy, in combination with standard of care (SoC) therapy in patients with relapsed acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukaemia (CML). This marks the first time bexmarilimab will be assessed as part of a clinical study in hematologic malignancies. "We are pleased that our IND application was cleared to proceed, and we can further explore the strong scientific rationale for combining bexmarilimab and azacitidine," said Marie-Louise Fj
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!